FDA Dumps Rigid Methods Rule to Streamline Enforcement Testing
Published Date: 2/19/2026
Rule
Summary
The FDA is officially scrapping a rule that told them which testing methods to use when no specific method was required by law. This change affects anyone involved in FDA enforcement programs but won’t cost extra or cause delays. The new rule kicks in on March 23, 2026, making things simpler and more flexible for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Validation and accreditation remain required
FDA states the revocation does not permit use of unvalidated methods and that methods used by FDA will continue to undergo qualification, validation, and fitness-for-use, including under ISO/IEC 17025 accreditation frameworks and the Laboratory Accreditation for Analyses of Foods (LAAF) program where applicable.
FDA drops AOAC default rule
The FDA removed 21 CFR 2.19, which said the Agency would default to AOAC (13th Ed., 1980) methods in enforcement programs when no method is specified by law. The revocation becomes effective March 23, 2026 and means FDA is no longer required to use that single compendium as its default.
No monetized costs or savings
FDA estimates the final rule will produce $0 in annualized monetized costs and $0 in monetized benefits (at both 3% and 7% discount rates, annualized over 10 years). The Agency also certified the rule will not have a significant economic impact on a substantial number of small entities.
FDA will list preferred methods in guidance
Instead of relying on a single incorporated compendium, FDA will identify preferred and validated analytical methods in documents that can be updated more frequently (for example, Agency methods compendia, compliance program guidance, and other resources). This is intended to allow more flexibility and quicker updates as science advances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-03284 — Amendment of Class D, Class E2, Class E4 and Class E5 Airspace Over Patuxent River, MD
The FAA is updating the airspace rules around Patuxent River Naval Air Station in Maryland to better cover all flight operations and remove outdated navigation references. These changes affect pilots flying under instrument flight rules and take effect on May 14, 2026. No new fees or costs are involved—just clearer, safer skies!
Next: 2026-03286 — Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community
Starting March 23, 2026, the FDA is canceling old rules that let the U.S. and European Union share certain drug and medical device inspection reports. These rules are outdated because a newer agreement from 2017 already covers this sharing. Companies making medicines and medical devices in both places should note this change, but it won’t add extra costs or delays.